

BIBLIOGRAPHY

- Acocella, G. and Conti, R. 1980. Interaction of rifampicin with other drugs. *Tubercel.* 61 : 171-177.
- Andrew, P. 1988. Perspectives in antiinfective therapy. In G.G. Jackson, H.D. Schlumberger and H.T. Zeiler (eds.). *Proceedings of an International Symposium* (August 31 - September 3), pp. 68-72. Washington D.C. : Vieweg, Braunschweig.
- Bachmann, K.A. and Jauregui, L. 1993. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status *in vivo*. *Xenobiotica.* 23 : 307-315.
- Backman, J.T., Olkkola, K.T. and Neuvonen, P.J. 1996. Rifampicin drastically reduces plasma concentrations and effects of oral midazolam. *Clin. Pharmacol. Ther.* 59 : 7-13.
- Barbarash, R.A., 1985. Verapamil-rifampicin interaction. *Drug Intell. Clin. Pharmacol.* 19 : 559-560.
- Barditch-Crovo, P., Trapnell, C.B., Ette, E., Zacur, H.A., Coresh, J., Rocco, L.E., Hendrix, C.W. and Flexner, C. 1999. The effects of rifampicin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. *Clin. Pharmacol. Ther.* 65 : 428-438.
- Benet, L.Z., Mitchell, J.R. and Sheiner, L.B. 1991. Pharmacokinetics : the dynamics of drug absorption, distribution and elimination. In A.G. Gilman and L.S. Goodman (eds.), *Pharmacological Basis of Therapeutics* (8th ed.), pp. 3-32. New York : Pergamon Press.

- Bittencourt, P.R.M., Gracia, C.M., Martins, R., Fernandes, A.G., Diekmann, H.W. and Jung, W. 1992. Phenytoin and carbamazepine decrease oral bioavailability of praziquantel. *Neurology*. 42 : 492-496.
- Boman, G., Hanngren, A. and Malmberg, A.S. 1971. Drug interaction : decreased serum concentrations of rifampicin when given with P.A.S. *Lancet*. 17 : 800.
- Boman, G. 1974. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid and isoniazid. *Eur. J. Clin. Pharmacol.* 7 : 215-225.
- Borcherding, S.M., Bastian, T.L., Self, T.H., Abou-Shala, N., Leduc, B.W. and Lalonde, R.L. 1992. Two-and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism. *Antimicrob. Agents Chemother.* 36 : 1553-1558.
- Borin, M.T., Chambers, J.H., Carel, B.J., Gagnon, S. and Freimuth, W.W. 1997. Pharmacokinetic study of the interaction between rifampicin and delavirdine mesylate. *Clin. Pharmacol. Ther.* 61 : 544-553.
- Budavari, S., O'Neil, M.J., Smith, A. and Heckelman, P.E. 1989. *The merck Index*. (11th ed.), 1222 pp. U.S.A. : Merck & Co., Inc.
- Bunnag, D. and Harinasuta, T. 1983. Studies on chemotherapy of human opisthorchiasis : III minimum effective dose of praziquantel. *Southeast Asian. J. Trop. Med. Public Health.* 12 : 413-417.
- Burger, D.M., Meenhorst, P.L., Koks, C.H.W. and Beijnen, J.H. 1993. Pharmacokinetic interaction between rifampicin and zidovudine. *Antimicrob. Agents Chemother.* 37 : 1426-1431.

- Bussey, H.I., Merrit, G.J. and Hill, E.G. 1984. The influence of rifampin on quinidine and digoxin. *Arch. Intern. Med.* 144 : 1021-1023.
- Castro, N., Medina, R., Sotelo, J. and Jung, H. 2000. Bioavailability of praziquantel increases with concomitant administration of food. *Antimicrob. Agents Chemother.* 44(10) : 2903-2904.
- Chambers, H.F. and Jawetz, E. 1998. Antimycobacterial drugs. In B.G. Katzung (ed.), *Basic and Clinical Pharmacology* (7th ed.), pp. 770-779. New Jersey : Prentice-Hall International Inc.
- Chenhsu, R.Y., Loong, C.C., Chou, M.H., Lin, M.F. and Yang, W.C. 2000. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. *The Annals of Pharmacotherapy.* 34 : 27-31.
- Combalbert, J., Fabre, I., Fabre, G., Dalet, I. and Derancourt, J. 1989. Metabolism of cyclosporin A : I.V. purification and identification of the rifampicin-inducible human liver cytochrome P450 (Cyclosporin A oxidase) as a product of P-450 III a gene subfamily. *Drug Metab Dispos.* 17 : 197-207.
- Correia, M.A. 1998. Drug biotransformation. In B.G. Katzung (ed.), *Basic and Clinical Pharmacology* (7th ed.), pp. 50-61. New Jersey : Prentice-Hall International Inc.
- Dachman, W.D., Adubofour, K.O., Bikin, D.S., Johnson, C.H., Mullin, P.D. and Winograd, M. 1994. Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. *J. Infect. Dis.* 169 : 689-691.

- Diekmann, H.W., Schneidereit, M. and Overbosch, D. 1989. Inhibitory effects of cimetidine ketoconazole and miconazole on the metabolism of praziquantel. *Acta Leidensia*. 57(2) : 217-228.
- Dilger, K., Hofmann, U. and Klotz, U. 2000. Enzyme induction in the elderly: effect of rifampicin on the pharmacokinetics and pharmacodynamics of propafenone. *Clin. Pharmacol. Ther.* 67 : 512-520.
- Doble, N., Shaw, R., Rowland-Hill, C., Lush, M., Warnock, D.W. and Keal, E.E. 1988. Pharmacokinetic study of the interaction between rifampicin and ketoconazole. *J. Antimicrob. Chemother.* 21 : 633-635.
- Ebert, U., Thong, N.Q., Oertei, R. and Kirch W. 2000. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. *Eur. J. Clin. Pharmacol.* 56 : 299-304.
- Freitag, V.L., Skifton, R.D. and Lake, K.D. 1999. Effect of short-term rifampicin on stable cyclosporine concentrations. *The Annals of Pharmacotherapy*. 33 : 871-872.
- Fromm, M.F., Busse, D., Kroemer, H.K. and Eichelbaum, M. 1996. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. *Hepatology*. 24 : 796-801.
- Fromm, M.F., Eckhardt, K., Li, S., Schanzle, G., Hofmann, U., Mikus, G. and Eichelbaum, M. 1997. Loss of analgesic effect of morphine due to coadministration of rifampin. *Pain*. 72 : 261-267.
- Gallicano, K.D., Sahai, J., Shukla, V.K., Seguin, I., Pakuts, A., Kwok, D., Foster, B.C. and Cameron, D.W. 1999. Induction of zidovudine

glucuronidation and amination pathways by rifampicin in HIV-infected patients. *Br. J. Clin. Pharmacol.* 48 : 168-179.

Garfield, J.W., Kreek, M.J. and Giush, L.M. 1975. Rifampin-methadone interaction. *American Review of Respiratory Diseases.* 3 : 926.

Gault, H., Langerich, L., Dawe, M. and Fine, A. 1984. Digoxin-rifampin interaction. *Clin. Pharmacol. Ther.* 35 : 752-754.

Gibaldi, M. 1991. Compartment and Noncompartment pharmacokinetics. In M. Gibaldi (ed.), *Biopharmaceutics and Clinical Pharmacokinetics* (4th ed.), pp. 14-23. UK, Breckenham: Lea and Febiger Ltd.

Gillum, J.G., Sesler, J.M., Bruzzese, V.L., Israel, D.S. and Polk, R.E. 1996. Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. *Antimicrob. Agents Chemother.* 40 : 1866-1869.

Giorgi, M., Salvatori, A.P., Soldani, G., Giusiani, M., Lungo, V., Gervasi, P.G. and Mengozzi, G. 2001. Pharmacokinetics and microsomal oxidation of praziquantel and its effect on the P450 system in three-month-old lambs infested by *Fasciola hepatica*. *J. vet. Pharmacol. Therap.* 24(4) : 251-259.

Goldsmith, R.S. 2001. Clinical pharmacology of the anthelmintic drugs. In B.G. Katzung (ed.), *Basic and Clinical Pharmacology* (8th ed.), pp. 903-922. New York: McGraw-Hill.

Gonzalez, F.J. and Idle, J.R. 1994. Pharmacogenetic phenotyping and genotyping present status and future potential. *Clin. Pharmacokinet.* 26 : 59-70.

- Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.P., Richter, O.V., Zundler, J. and Kroemer, H.K. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. *J. Clin. Invest.* 104(2) : 147-153.
- Guay, D.R. 1998. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. *Pharmacotherapy.* 18 : 1195-1204.
- Guengerich, F.R. 1988. Oxidation of 17 α -ethynylestradiol by human liver cytochrome P450. *Molecular Pharmacology.* 33 : 500-508.
- Guiniady, M.A., Touny, M.A., Abdel-Bary, M.A., Abdel-Fatah, S.A. and Metwally, A. 1994. Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. *Am. J. Trop. Med. Hyg.* 51(6) : 809-818.
- Halpert, J.R. 1995. Structural basis of selective cytochrome P450 inhibition. *Annual Review of Pharmacology and Toxicology.* 35 : 29-53.
- Hamma, M.A., Bruce, M.A., Haehner-Daniels, B.D. and Hall, S.D. 2001. The effect of rifampicin administration on the disposition of fexofenadine. *Clin. Pharmacol. Ther.* 69 : 114-121.
- Hebert, M.F., Roberts, J.P., Prueksaritanont, T. and Benet, L.Z. 1992. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. *Clin. Pharmacol. Ther.* 52 : 453-457.
- Hebert, M.F., Fisher, R.M., Marsh, C.L., Dressler, D. and Bekersky, I. 1999. Effects of rifampicin on tacrolimus pharmacokinetics in healthy volunteers. *J. Clin. Pharmacol.* 39 : 91-96.

- Heimark, L.D., Gibaldi, M., Trager, W.F., O' Reilly, R.A. and Goulart, D.A. 1987. The mechanisms of warfarin-rifampicin drug interaction in human. *Clin. Pharmacol. Ther.* 42 : 388-394.
- Holdiness, M.R. 1984. Clinical pharmacokinetics of the antituberculosis drugs. *Clin. Pharmacokinet.* 9 : 511-544.
- Homeida, M., Leahy W., Copeland, S., Ali, M.M.M. and Harron, D.W.G. 1994. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. *Trop. Med. Parasitol.* 88(5) : 551-559.
- Hoppa, K. 1999. Prehepatic metabolism of drugs-a mechanism for low and variable oral bioavailability. *Pediatr. Nephrol.* 13 : 85-89.
- Jadsri, S. and Noojoy, A. 1999. A study of liver fluke infection in Sukhothai, Thailand. *Southeast Asian J Trop Med Public Health.* 30(3) : 588-593.
- Jaruratanasirikul, s. and Sriwiriyan S. 1998. Effects of rifampicin on the pharmacokinetics of itraconazole in normal normal volunteers and AIDS patients. *Eur. J. clin. Pharmacol.* 54 : 155-158.
- Jongsuksuntigul, P. and Imsomboon, T. 1998. Epidemiology of opisthorchiasis and national control program in Thailand. *Southeast Asian J Trop Med Public Health.* 29(2) : 327-332.
- Jung, H., Hurtado, M., Sanchez, M., Medina, M.T. and Sotelo, J. 1990. Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis. *Clin. Neuropharmacol.* 13(6) : 559-564.
- Jung, H., Medina, R., Castro, N. Corona, T. and Sotelo, J. 1997. Pharmacokinetic study of praziquantel administered alone and in

combination with cimetidine in a single-day therapeutic regimen.

Antimicrob. Agents Chemother. 41(6) : 1256-1259.

Kelly, H., Kelly, H.W., Couch, R.C., Davis, R.L., Cushing, A.H. and Knorr, R.

1988. Interactions of chloramphenicol and rifampicin. *J. Pediatr.*

112 : 817-820.

Khamboonruang, C. 1991. On emerging problems in food-borne parasitic

zoonosis : impact on agriculture and public health. *Southeast Asian J*

Trop Med Public Health. 22(suppl) : 1-7.

King, C.H. and Mahmoud, A.F. 1989. Drugs five years later : praziquantel.

Ann. Intern. Med. 110 : 290-296.

Kivisto, K.T., Villikka, K., Nyman, L., Anttila M. and Neuvonen, P.J. 1998.

Tamoxifen and toremifene concentrations in plasma are greatly

decreased by rifampin. *Clin. Pharmacol. Ther.* 64 : 48-54.

Kolars, J.C., Schmiedlin-Ren, P., Schuetz, J.D., Fang, C. and Watkins, P.B.

1992. Identification of rifampin-inducible P450III_{A4} (CYP3A4) in

human small bowel enterocytes. *J. Clin. Invest.* 90 : 1871-1878.

Kyrklund, C., Backman, J.T., Kivisto, K.T., Neuvonen, M., Laitila, J. and

Neuvonen, P.J. 2000. Rifampicin greatly reduces plasma simvastatin

and simvastatin acid concentrations. *Clin. Pharmacol. Ther.* 68 :

592-597.

Lee, K.H., Shin, J.G., Chong, W.S., Kim, S., Lee, J.S., Jang, I.J. and Shin,

S.G. 1993. Time course of the changes in prednisolone

pharmacokinetics after co-administration or discontinuation of

rifampin. *Eur. J. Clin. Pharmacol.* 45 : 287-289.

- Leopold, G., Unguthem, W., Groll, E., Diekmann, H.W., Nowak, H. and Wegner, D.H.G. 1978. Clinical pharmacology in normal volunteers of praziquantel : A new drug against schistosomes and cestodes. *Eur. J. Clin. Pharmacol.* 14 : 281-291.
- Lin, J.H. and Lu, A.Y.H. 1998. Inhibition and induction of cytochrome P450 and the clinical implications. *Clin. Pharmacokinet.* 35 : 361-390.
- Mandell, G.L. and Sandle, M.A. 1996 Antimicrobial agents : drug used in the chemotherapy of tuberculosis and leprosy. In L.S. Goodman and A.G. Gilman (eds.), *Pharmacological Basis of Therapeutics* (8th ed.), pp. 1146-1164. New York: McGraw-Hill.
- Mandour, M.M., Turabi, H., Homeida, M., Sadig., T., Ali, H., Bennett, J.L., Leahey, W.J. and Harron, D.W.G. 1990. Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. *Trans. R. Soc. Trop. Med. Hyg.* 84 : 389-393.
- Masimirembwa, C.M., Naik, Y.S. and Hasler, J. A. 1993. Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics of praziquantel in rat. *Eur. J. Drug Metab. pharmacokinet.* 18 (3) : 261-264.
- Masimirembwa, C.M., Naik, Y.S. and Hasler, J. A. 1994(a). The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans. *Biopharm. Drug Dispos.* 15 : 33-34.
- Masimirembwa, C.M. and Hasler, J. A. 1994(b). Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors. *Biochem. Pharmacol.* 48 : 1779-1783.

- McDonald, L.C., Archibald, L.K., Rheapumikankit, S., Tansuphaswadikul, S., Eampokalap, B., Nwanyanawu, O., Kazembe, P., Dobbie, H., Reller, L.B. and Jarvis, W.R. 1999. Unrecognised *Mycobacterium tuberculosis* bacteraemia among hospital inpatients in less developed countries. *Lancet*. 354 : 1159-1163.
- Mcnicol, M.W., Campbell, I.A. and Jenkins, P.A. 1995. Clinical features and management. In R. Brewis, B. Corrin, D.M. Geddes and G.J. Gibson (eds.), *Respiratory Medicine* (2nd ed.), pp. 805-832. London: Saunders Compang Ltd.
- Meier, H. and Blaschke, G. 2000. Capillary electrophoresis-mass spectrometry, liquid chromatography-mass spectrometry and nanoelectrospray-mass spectrometry of praziquantel metabolites. *J. Chromatogr. B*. 748 : 221-231.
- Metwally, A., Bennett, J.L., Botros, S. and Ebeid, F. 1995. Effect of cimetidine, bicarbonate and glucose on the bioavailability of different formulations of praziquantel. *Arzneimittelforschung*. 45(4) : 516-518.
- Miguet, J.P., Mavier, P., Soussy, C.J. and Dhumeaux, D. 1977. Induction of hepatic microsomal enzymes after brief administration of rifampicin in man. *Gastroenterology*. 72 : 924-926.
- Moreno, S., Podzamczar, D., Blazquez, R., Iribabarren, J.A., Ferrer, E., Reparaz, J., Pena, J.M., Cabrero, E. and Usan, L. 2001. Treatment of tuberculosis in HIV-infected patients : safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampicin. *AIDS*. 15(9) : 1185-1187.

- Na-Bangchang, K., Karbwang, J., Pungpak, S., Radomyos, B. and Bunnag, D. 1993. Pharmacokinetics of praziquantel in patients with opisthorchiasis. *Southeast Asian J Trop Med Public Health*. 24(4) : 717-723.
- Na-Bangchang, K., Vanijanonta, S. and Karbwang, J. 1995. Plasma concentrations of praziquantel during the therapy of neurocysticercosis with praziquantel in the presence of antiepileptics and dexamethasone. *Southeast Asian J. Trop. Med. Public Health*. 26(1) : 120-123.
- Niemi, M., Backman, J.T., Neuvonen, M., Neuvonen, P.J. and Kivisto, K.T. 2000. Rifampicin decreases the plasma concentrations and effects of repaglinide. *Clin. Pharmacol. Ther.* 68 : 495-500.
- Niemi, M., Backman, J.T., Neuvonen, M., Neuvonen, P.J. and Kivisto, K.T. 2001. Effects of rifampicin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. *Clin. Pharmacol. Ther.* 69 : 400-406.
- Ofori-Adjei, D., Adjepon-Yamoah, K.K., Lindstrom, B. 1988. Oral praziquantel kinetics in normal and *Schistosoma haematobium*-infected subjects. *Ther. Drug Monitoring*. 10(1) : 45-49.
- O' Reilly, R.A. 1974. Interaction of sodium warfarin and rifampicin. *Ann. Intern. Med.* 81 : 337-340.
- O' Reilly, R.A. 1975. Interaction of chronic daily warfarin therapy and rifampicin : studies in man. *Ann. Intern. Med.* 83 : 501-508.
- Patzschke, K., Putter, J., Wagner, L.A., Horster, F.A. and Diekmann, H.W. 1979. Serum concentrations and renal excretion in humans after oral

- administration of praziquantel : Results of three determination methods. *Eur. J. Drug Metab. Pharmacokinet.* 3 : 149-156.
- Pea, F. and Furlanut, M. 2001. Pharmacokinetics aspects of treating infections in the intensive care unit : focus on drug interactions. *Clin. Pharmacokinet.* 40 : 833-868.
- Pearson, R.D. and Guerrant, R.L. 1983. Praziquantel : a major advance in anthelmintic therapy. *Ann. Intern. Med.* 99 : 195-198.
- Pehrson, P.O., Bengtsson, E., Diekmann, H.W. and Groll, E. 1983. Treatment with praziquantel in a patient with schistosomiasis and chronic renal failure. *Trans. R. Soc. Trop. Med. Hyg.* 77(5) : 687-688.
- Polk, R.E., Brophy, D.F., Israel, D.S., Patron, R., Sadler, B.M., Chittick, G.E., Symonds, W.T., Lou, Y., Kristoff, D. and Stein, D.S. 2001. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. *Antimicrob. Agents Chemother.* 45(2) : 502-508.
- Prober, C.G. 1985. Effect of rifampicin on chloramphenicol levels. *N. Engl. J. Med.* 312 : 788-789.
- Radomyos, B., Wongsaroj, T., Wilairatana, P., Radomyos, P., Pracvanich, R., Meesomboon, V. and Jongsuksuntikul, P. 1998. Opisthorchiasis and intestinal fluke infections in Northern Thailand. *Southeast Asian J. Trop. Med. Public Health.* 29(1) : 123-127.
- Reynolds, J.E.F., Parfitt, K., Parsons, A.V. and Sweetman, S.C. 1993. *Martindale The Extra Pharmacopoeia* (30th ed.), 2363 pp. London: The Pharmaceutical Press.

- Ribera, E., Pou, L., Fernandez-Sola, A., Campos, F., Lopez, R.M., Ocana, I., Ruiz, I. and Pahissa, A. 2001. Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients. *Antimicrob. Agents Chemother.* 45(11) : 3238-3241.
- Ridtitid, W., Wongnawa, M., Mahathanatrakul, W., Chaipol, P. and Sunbhanich, M. 2000. Effect of rifampicin on plasma concentrations of mefloquine in healthy volunteers. *J. Pharm. Pharmacol.* 52 : 1265-1269.
- Ridtitid, W., Wongnawa, M., Mahathanatrakul, W., Punyo, J. and Sunbhanich, M. 2002. LC determination of praziquantel in human plasma. *J. Pharm. Biomed. Anal.* 28 : 181-186.
- Schepmann, D. and Blaschke, G. 2001. Isolation and identification of 8-hydroxypraziquantel as a metabolite of the antischistosomal drug praziquantel. *J. Pharm. Biomed. Anal.* 26 : 791-799.
- Self, T.H. and Morris, T. 1980. Interaction of rifampicin and chlorpropamide. *Chest.* 77 : 800-801.
- Siegler, D.I., Bryant, M., Burley, D.M., Citron, K.M. and Standen, S.M. 1974. Effect of meals on rifampicin absorption. *Lancet.* 27 : 197-198.
- de Silva, N., Guyatt, H. and Bundy, D. 1997. Anthelmintics : A comparative review of their clinical pharmacology. *Drugs.* 53(5) : 769-788.
- Sotelo, J. and Jung, H. 1998. Pharmacokinetic optimisation of the treatment of neurocysticercosis. *Clin. Pharmacokinet.* 34(6) : 503-515.
- Strayhorn, V.A., Bacicwicz, A.M., Self, T.H. 1997. Update on rifampicin drug interactions III. *Arch. Intern. Med.* 157 : 2453-2458.

- Supanvanich, S., Supanvanich, K. and Pawabut, P. 1982. Field trial of praziquantel in human opisthorchiasis in Thailand. *Southeast Asian J. Trop. Med. Public Health.* 12 : 598-601.
- Syvalathi, E.K.G., Pihlajamaki, K.K. and Lisalo, E.J. 1974. Rifampicin and drug metabolism. *Lancet.* 2 : 232-233.
- Syvalathi, E.K.G., Pihlajamaki, K.K. and Lisalo, E.J. 1975. Effect of tuberculostatic agents on the response of serum growth hormone and immunoreactive insulin to intravenous tolbutamide and on the half-life of tolbutamide. *Intern. J. Clin. Pharmacol. Toxicol. Ther.* 13 : 83-89.
- Tracy, J.W. and Webster, L.T. 2001. Drugs used in the chemotherapy of helminthiasis. In J.G. Hardman and L.E. Limbird (eds.), *Goodman & Gilman's The Pharmacological Basis of Therapeutics* (10th ed.) pp. 1121-1140. New York: McGraw-Hill.
- Vazquez, M.L., Jung, H. and Sotelo, J. 1987. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. *Neurology.* 37 : 1561-1562.
- Venkatesan, K. 1992. Pharmacokinetic drug interactions with rifampicin. *Clin. Pharmacokinet.* 22 : 47-65.
- Villikka, K., Kivisto, K.T., Backman, J.T., Olkkola, K.T. and Neuvonen, P.J. 1997a. Triazolam is ineffective in patients taking rifampicin. *Clin. Pharmacol. Ther.* 61 : 8-14.
- Villikka, K., Kivisto, K.T., Luurila, H. and Neuvonen, P.J. 1997b. Rifampicin reduces plasma concentrations and effects of zolpidem. *Clin. Pharmacol. Ther.* 62 : 629-634.

- Villikka, K., Kivisto, K.T. and Neuvonen, P.J. 1999. The effect of rifampicin on the oral and intravenous ondansetron. *Clin. Pharmacol. Ther.* 65 : 377-381.
- Vivatanasesth, P., Sornmani, S., Schelp, F.P. et al. 1982. Mass treatment of opisthorchiasis in Northeast Thailand. *Southeast Asian J. Trop. Med. Public Health.* 13 : 609-702.
- Wanwimolruk, S., Wong, S.M., Znang, H., Coville, P.F. and Walker, R.J. 1995. Metabolism of quinine in man : identification of a major metabolite, and effects of smoking and rifampicin pretreatment. *J. Pharm. Pharmacol.* 47 : 975-963.
- Watt, G., White, N.J., Padre, L. Ritter, W., Fernando, M.T., Ranoa, C.P. and Laughlin, L.W. 1988. Praziquantel pharmacokinetics and side effects in *Schistosoma japonicum*-infected patients with liver disease. *J. Infect. Dis.* 157(3) : 530-535.
- WHO, 1998. Tuberculosis fact sheet. *Global Tuberculosis Programme.*
- William, A. and Petri, Jr. 2001. Antimicrobial agents. In J.G. Hardman and L.E. Limbird (eds.), *Goodman & Gilman's The Pharmacological Basis of Therapeutics.* (10th ed.), pp. 1273-1294. New York: McGraw-Hill.
- Windholz, M., Budavari, S., Stroumtsos, L.Y. and Fertig, M.N. 1976. *The Merck Index.* (9th ed.), 1068 pp. U.S.A.: Merck & Co., Inc.
- Zhang, Q.Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J. and Kaminsky, L.S. 1999. Characterization of human small intestinal cytochromes P-450. *Drug Metab. Dispos.* 27 : 804-809.

- Zhang, Y.J. and Quan, Y.Z. 1997. Involvement of cytochrome P4503A in the monohydroxylation of ring A of praziquantel in rat liver microsomes. *Yao Xue Xue Bao*. 32(1) : 5-10.
- Zhou, H.H., Feng, H.J., Huang, S.L. and Wang, W. 1997. Inducing effect of rifampin on CYP2C19 is related to gene dose. *Clin. Pharmacol. Ther.* 61 : 277.